Printer Friendly

Browse Non-small cell lung cancer topic

Drug therapy subtopic

Articles

1-271 out of 271 article(s)
Title Author Type Date Words
FDA approves Genentech's Tecentriq as adjuvant treatment for NSCLC. Oct 15, 2021 192
TOP NEWS: AstraZeneca early-stage lung cancer drug gets EU approval. May 28, 2021 233
AstraZeneca posts positive final-stage trial results for lung cancer treatment. May 8, 2021 533
AstraZeneca reports positive results in Phase 3 lung cancer drug trial. Financial report May 7, 2021 209
AstraZeneca's Tagrisso recommended in E.U. for treatment of EGFR lung cancer. Disease/Disorder overview Apr 26, 2021 187
Active Biotech and NeoTX get green light for Phase IIa trial of anti-cancer immunotherapy. Apr 19, 2021 165
Active Biotech and NeoTX get green light for Phase IIa trial of anti-cancer immunotherapy. Apr 19, 2021 164
Active Biotech and NeoTX get green light for Phase IIa trial of anti-cancer immunotherapy. Apr 19, 2021 163
AstraZeneca wins approval in China for early-stage lung cancer treatment Tagrisso. Apr 15, 2021 316
Novartis drug misses primary endpoint in lung cancer trial. Mar 9, 2021 157
'Revolutionary' new cancer treatment builds on COVID-19 jab tech. Arab News Mar 6, 2021 242
China's administrator approves Harbour BioMed's Investigational New Drug application for HBM4003. Feb 26, 2021 167
China's administrator approves Harbour BioMed's Investigational New Drug application for HBM4003. Feb 26, 2021 163
Potential seen for Takeda lung cancer treatment. Feb 15, 2021 537
EMD Serono's TEPMETKO (tepotinib) receives US FDA approval. Feb 4, 2021 165
EMD Serono's TEPMETKO (tepotinib) receives US FDA approval. Feb 4, 2021 169
Takeda Pharmaceutical Gets Japan Green Light For Lung Cancer Drug. Jan 22, 2021 170
AstraZeneca says EU, UK approve cancer drug for additional dosing option. Jan 16, 2021 336
EU Okays New Dosing Option For Lung Cancer Drug Imfinzi - AstraZeneca. Jan 15, 2021 225
Genprex meets manufacturing requirements for lung cancer drug REQORSA ahead of combination trials. Jan 14, 2021 372
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation. Li, Jing; Li, Hongqi; Wang, Yingjie; Liu, Junyang; Wang, Xuan; Pang, Haifeng; Chang, Dongshu; Di, Yu Report Jul 31, 2020 5499
Genprex to Focus Its Clinical Efforts on Oncoprex in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer. Feb 11, 2020 684
Genprex prioritizing Oncoprex development in combo with AstraZeneca's Tagrisso to treat non-small cell lung cancer. Feb 6, 2020 667
US FDA grants Eli Lilly priority review for selpercatinib New Drug Application. Jan 30, 2020 214
US FDA grants Eli Lilly priority review for selpercatinib New Drug Application. Jan 30, 2020 210
Evotec partners with Indivumed for second joint drug discovery programme. Jan 23, 2020 197
Evotec partners with Indivumed for second joint drug discovery programme. Jan 23, 2020 193
Genprex wins FDA FTD for Gene Therapy targeting lung cancer. Jan 22, 2020 211
Genprex wins FDA FTD for Gene Therapy targeting lung cancer. Jan 22, 2020 207
Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy. Shanthi Rexaline Jan 21, 2020 339
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics. Shanthi Rexaline Jan 16, 2020 785
Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1, 25-Dihydroxyvitamin [D.sub.3] in Non-Small-Cell Lung Cancer: A Case Report and Literature Review. Ogawa, Takunori; Miyata, Jun; Fukunaga, Koichi; Kawana, Akihiko; Inoue, Takashi Jan 1, 2020 2339
Synergistic Effect of Network-Based Multicomponent Drugs: An Investigation on the Treatment of Non-Small-Cell Lung Cancer with Compound Liuju Formula. Su, Xing; Jiang, Meng; Li, Yueping; Zhu, Jinglin; Zheng, Chunli; Chen, Xuetong; Zhou, Jun; Xiao, Wei Jan 1, 2020 8243
FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer. Dec 4, 2019 1548
Afatinib Associated Papulopustular Phototoxic Eruptions: A Novel Case Report. Begum, U. Zeenath; Krishnakanth, M.; Rajesh, Gayathri; Veeraraghavan, Mahalakshmi; Sudha, R.; Muruga Clinical report Dec 1, 2019 747
LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. Ciccarese, Francesco; Zulato, Elisabetta; Indraccolo, Stefano Nov 30, 2019 12131
Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Alrifai, Taha; Ali, Faisal Shaukat; Saleem, Sameer; Ruiz, Diana Carolina Miranda; Rifai, Dana; Youna Nov 30, 2019 1964
Breckenridge wins final FDA approval for launch of generic Tarceva. Nov 13, 2019 157
Breckenridge wins final FDA approval for launch of generic Tarceva. Nov 13, 2019 153
Breast and kidney cancer drugs get approval for use across Scotland's NHS. Nov 11, 2019 373
More progress on cancer medicines. Nov 4, 2019 324
More cancer drugs confirmed - even more on horizon. Oct 7, 2019 310
Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival -- study. Reuters News Service Sep 28, 2019 411
Amgen Receives Good Results In Trial Of Proposed Lung Cancer Drug. Sep 9, 2019 140
Roche Gets Thumbs Up In Europe To Expand Lung Cancer Drug. Sep 6, 2019 163
Novartis Lung Cancer Treatment Gets US FDA Breakthrough Therapy. Sep 6, 2019 134
Astrazeneca set back in lung cancer drug trial. Aug 22, 2019 164
Rozltrek FDA Approved for Hard-to-Treat NTRK Fusion-Positive Tumors, Available at Biologics by McKesson. Aug 22, 2019 560
AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study. Aug 21, 2019 319
Genentech (SIX: RO, ROG; OTCQX: RHHBY) - FDA Approves Genentech's Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors -- 15/8/2019. Aug 20, 2019 645
Rozlytrek Approved to Treat Tumors With NTRK Gene Fusion; Drug also approved to treat metastatic non-small cell lung cancer with ROS1-positive tumors. Aug 19, 2019 327
US FDA grants approval to Roche's Rozlytrek. Aug 19, 2019 227
US FDA grants approval to Roche's Rozlytrek. Aug 19, 2019 223
FDA Approves Genentech's Rozlytrek for People with ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors. Aug 19, 2019 982
FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours. Aug 16, 2019 1528
Roche's Rozlytrek Gains US Approval For Two Types Of Cancer. Aug 16, 2019 135
Correction - FDA approves Roche's Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours. Correction notice Aug 16, 2019 1748
FDA approves Genentech's Rozlytrek in ROS1-Positive NSCLC. Aug 15, 2019 125
Amgen (NASDAQ: AMGN) - Amgen And Allergan's MVASI[TM] (bevacizumab-awwb) And KANJINTI[TM] (trastuzumab-anns) Now Available In The United States -- 18/7/2019. Jul 25, 2019 757
Amgen (NASDAQ:AMGN) - Amgen And Allergan's MVASI[TM] (bevacizumab-awwb) And KANJINTI[TM] (trastuzumab-anns) Now Available In The United States -- 18/7/2019. Jul 22, 2019 743
Amgen, Allergan say Mvasi, Kanjinti now available in U.S. Jul 19, 2019 118
WHO keeps key lung cancer drugs off its essential medicines list. Jul 10, 2019 663
Sandoz introduces Gefitinib generic cancer treatment. Jul 4, 2019 177
Sandoz introduces Gefitinib generic cancer treatment. Jul 4, 2019 173
Pfizer Receives US FDA Approval for Its Oncology Biosimilar, Zirabev. Jul 2, 2019 322
Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology. Meng, Ziqi; Liu, Xinkui; Wu, Jiarui; Zhou, Wei; Wang, Kaihuan; Jing, Zhiwei; Liu, Shuyu; Ni, Mengwei Jun 30, 2019 8348
Pfizer announces FDA approval for Zirabev for treatment of five types of cancer. Jun 28, 2019 102
TOP NEWS: Two AstraZeneca Cancer Drugs Have Positive Trial Results. Jun 3, 2019 458
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naive Vision of a Single Biomarker. Signorelli, Diego; Giannatempo, Patrizia; Grazia, Giulia; Aiello, Marco Maria; Bertolini, Federica; May 31, 2019 11914
Transgene enrols last patient in phase two trial assessing lung cancer drug TG4010 in combination with Opdivo and chemotherapy. May 29, 2019 255
Transgene enrols last patient in phase two trial assessing lung cancer drug TG4010 in combination with Opdivo and chemotherapy. May 29, 2019 251
Transgene begins treatment of last lung cancer patient under the Phase 2 trial of TG4010 in combination with Opdivo (nivolumab). May 28, 2019 310
Transgene begins treatment of last lung cancer patient under the Phase 2 trial of TG4010 in combination with Opdivo (nivolumab). May 28, 2019 306
Teva Announces Launch of a Generic Version of Tarceva Tablets in the United States. May 15, 2019 352
Merck & Company, Inc. (NYSE:MRK) - FDA Approves Expanded Monotherapy Label for Merck's KEYTRUDA[R] (pembrolizumab) -- 11/4/2019. Apr 15, 2019 420
Merck's Ketyruda granted expanded monotherapy label by FDA for NSCLC. Apr 11, 2019 149
Gritstone Oncology announces first patient dosed with GRANITE-001. Mar 21, 2019 156
Lilly's lung cancer drug Cyramza(R) (ramucirumab) meets primary endpoint in Phase 3 RELAY Trial. Mar 13, 2019 247
Lilly's lung cancer drug Cyramza(R) (ramucirumab) meets primary endpoint in Phase 3 RELAY Trial. Mar 13, 2019 243
European Medicines Agency's committee recommends Pfizer's lung cancer drug. Mar 5, 2019 188
European Medicines Agency's committee recommends Pfizer's lung cancer drug. Mar 5, 2019 184
New Indication for Alimta Combination. Feb 18, 2019 384
GSK, Merck KGaA partner to jointly develop cancer treatment M7824. Feb 5, 2019 222
Eli Lilly wins US FDA's approval for new indication of ALIMTA (pemetrexed for injection) and KEYTRUDA (pembrolizumab) combination for NSCLC. Feb 1, 2019 321
Eli Lilly wins US FDA's approval for new indication of ALIMTA (pemetrexed for injection) and KEYTRUDA (pembrolizumab) combination for NSCLC. Feb 1, 2019 317
Immunological Agents Used in Cancer Treatment. Simsek, Melih; Tekin, Salim Basol; Bilici, Mehmet Feb 1, 2019 4004
Eli Lilly says FDA granted approval for new indication for ALIMTA/KEYTRUDA combo. Jan 31, 2019 170
Innovation and Value Initiative Releases Open-Source Model for Assessing Value of EGFR+ Non-Small Cell Lung Cancer Treatment Sequences. Jan 31, 2019 582
FDA Approves Genentech's Tecentriq in Combination with Avastin and Chemotherapy for the Initial Treatment of People with a Specific Type of Metastatic Lung Cancer. Dec 11, 2018 624
Mirati Therapeutics passes US FDA's IND clearance of KRAS G12C Inhibitor, MRTX849. Nov 30, 2018 284
Mirati Therapeutics passes US FDA's IND clearance of KRAS G12C Inhibitor, MRTX849. Nov 30, 2018 280
Athenex initiates Phase 1/2 Oraxol study. Nov 26, 2018 132
New Data from Investigational Study of Lenvima and Keytruda Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd annual meeting. Nov 13, 2018 982
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting. Nov 9, 2018 1660
FDA Approves US Merck's Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC). Nov 2, 2018 353
Merck says FDA approves Keytruda in combo with carboplatin. Oct 30, 2018 151
Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC; Most patients who received targeted therapy based on plasma result achieved clinical response. Clinical report Oct 18, 2018 271
US FDA Approves Vizimpro for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer. Oct 1, 2018 699
Qiagen Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer. Oct 1, 2018 269
Qiagen receives FDA approval to expand use of EGFR test in lung cancer. Sep 28, 2018 102
Pfizer announces FDA approval for Vizimpro. Sep 27, 2018 265
Roche says FDA extends review period for Tecentriq by three months. Sep 6, 2018 140
Roche receives FDA Approval for Cobas EGFR Mutation Test v2 as Companion Diagnostic with Iressa in First-Line Treatment of Patients with Non-Small Cell Lung Cancer. Aug 27, 2018 378
FDA Approves Expanded Label for US Merck's Keytruda in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy for First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations. Aug 23, 2018 155
China National Drug Administration grants marketing authorisation to Roche's Alecensa. Aug 22, 2018 175
China National Drug Administration grants marketing authorisation to Roche's Alecensa. Aug 22, 2018 171
FDA grants regular approval for pembrolizumab combo for NSqNSCLC. Aug 20, 2018 115
FDA approves expanded label for Merck's Keytruda, Alimta combination. Aug 20, 2018 191
AstraZeneca receives Japanese regulatory approval for two major cancer drugs. Jul 4, 2018 309
AstraZeneca receives Japanese regulatory approval for two major cancer drugs. Jul 4, 2018 305
Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression. Saxena, Ashish Report Jul 1, 2018 1764
US FDA Approves Bristol-Myers Squibb sBLA for First-Line NSCLC Treatment Opdivo Plus Low-Dose Yervoy. Jun 27, 2018 185
Eli Lilly and Company passes US FDA approval for new indication for ALIMTA, carboplatin and KEYTRUDA combination for NSCLC. Jun 6, 2018 292
Eli Lilly and Company passes US FDA approval for new indication for ALIMTA, carboplatin and KEYTRUDA combination for NSCLC. Jun 6, 2018 288
Eli Lilly announces Alimta label expanded by FDA. Jun 5, 2018 223
Daiichi Sankyo Initiates Phase 2 Study of lung cancer drug DS-8201. Jun 1, 2018 250
Daiichi Sankyo Initiates Phase 2 Study of lung cancer drug DS-8201. Jun 1, 2018 246
Pfizer's Xalkori receives FDA breakthrough therapy designation in 2 indications. May 29, 2018 152
AstraZeneca reveals more solid data for Imfinzi cancer treatment. Clinical report May 25, 2018 226
AstraZeneca reveals more solid data for Imfinzi cancer treatment. Clinical report May 25, 2018 222
Roche's cancer immunotherapy TECENTRIQ (atezolizumab) granted FDA priority review for initial treatment of specific type of metastatic lung cancer. May 8, 2018 251
Roche's cancer immunotherapy TECENTRIQ (atezolizumab) granted FDA priority review for initial treatment of specific type of metastatic lung cancer. May 8, 2018 255
FDA Approves Drug Combo for Aggressive Thyroid Cancer; Dabrafenib + trametinib approved to treat BRAF-positive anaplastic thyroid cancer. May 7, 2018 257
US FDA Approves Expansion of Roche Mutation Test as Companion Diagnostic with Tagrisso for NSCLC Patients. Apr 24, 2018 369
AstraZeneca says FDA approves Tagrisso as 1st-line treatment for certain cancers. Apr 19, 2018 106
Roche expands indication for cobas EGFR Mutation Test v2. Apr 18, 2018 231
Developing liquid biopsy diagnostic testing for cancer immunotherapy selection in NSCLC patients. Pestano, Gary; Jensen-Long, Lisa Apr 1, 2018 1493
Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. Guerini-Rocco, Elena; Passaro, Antonio; Casadio, Chiara; De Luca, Valeria Midolo; Guarize, Juliana; Report Apr 1, 2018 7085
Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology? Ali, Greta; Bruno, Rossella; Savino, Mauro; Giannini, Riccardo; Pelliccioni, Serena; Menghi, Maura; Report Apr 1, 2018 7981
Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen Trometamol and Evaluation of In Vitro Characteristic Properties/Erlotinib HCl ve Deksketoprofen Trometamol Iceren Nanokohleatlarin Gelistirilmesi ve In Vitro Karakteristik Ozelliklerinin Degerlendirilmesi. Coban, Ozlem; Degim, Zelihagul Report Apr 1, 2018 3698
Roche issues challenge to Bristol, Merck cancer drugs with Tecentriq cocktail. Mar 26, 2018 349
Imfinzi (durvalumab) Approved for Treatment of Unresectable Stage III NSCLC by US FDA. Feb 21, 2018 321
AstraZeneca wins US FDA approval for IMFINZI (durvalumab) for treating unresectable Stage III non-small cell lung cancer. Feb 19, 2018 309
AstraZeneca wins US FDA approval for IMFINZI (durvalumab) for treating unresectable Stage III non-small cell lung cancer. Feb 19, 2018 305
QIAGEN passes US FDA's approval for expanded use of EGFR test for three additional gene mutations in lung cancer. Jan 19, 2018 209
QIAGEN passes US FDA's approval for expanded use of EGFR test for three additional gene mutations in lung cancer. Jan 19, 2018 205
FDA Expands Indication for Gilotrif to Include EGFR mutation-positive NSCLC. Jan 19, 2018 300
Boehringer announces expanded indication for Gilotrif for NSCLC patients whose tumors have certain EGFR mutations. Jan 17, 2018 277
Boehringer announces expanded indication for Gilotrif for NSCLC patients whose tumors have certain EGFR mutations. Jan 17, 2018 273
GeneCentric, G1 Form Research Collaboration to Study Subtyping Platform Use with CDK4/6 Inhibitor for Treatment of NSCLC. Jan 4, 2018 304
Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer. Yang, R.F.; Yu, B.; Zhang, R.Q.; Wang, X.H.; Li, C.; Wang, P.; Zhang, Y.; Han, B.; Gao, X.X.; Zhang, Report Jan 1, 2018 5456
Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy. Bitar, Sandy El; Weerasinghe, Chanudi; Charabaty, Elie El-; Odaimi, Marcel Jan 1, 2018 1799
Lung cancer: Stages and treatment options. Nov 27, 2017 628
Genentech Receives FDA Approval for Alecensa (Alectinib) for ALK-positive Metatstatic NSCLC. Nov 7, 2017 116
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer. Nov 2, 2017 388
Lung cancer treatment advances. Oct 30, 2017 117
Amgen & Allergan's MVASI (bevacizumab-awwb) approved by US FDA for five types of cancer. Sep 15, 2017 305
Amgen & Allergan's MVASI (bevacizumab-awwb) approved by US FDA for five types of cancer. Sep 15, 2017 301
Kadmon Receives Orphan Drug Designation for Tesevatinib for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer. Aug 8, 2017 236
Many seniors not treated for lung cancer: effective treatments exist for lung cancer, but there are risks and benefits with each option. Aug 1, 2017 888
Novartis wins US FDA approval to expand use of Zykadia for treating patients with metastatic non-small cell lung cancer. May 29, 2017 278
Novartis wins US FDA approval to expand use of Zykadia for treating patients with metastatic non-small cell lung cancer. May 29, 2017 274
Circulogene Adds Three Tests Supporting Personalised Treatment for Lung Cancer Patients. May 24, 2017 400
US FDA approves Merck's Keytruda in combination with pemetrexed and carboplatin. May 12, 2017 148
US FDA approves Merck's Keytruda in combination with pemetrexed and carboplatin. May 12, 2017 144
FDA Approves US Merck's Keytruda as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression. May 10, 2017 390
US FDA Grants Breakthrough Therapy Designation to Pfizer's Lorlatinib Next-Generation ALK/ROS1 Inhibitor for ALK-Positive Metastatic Non-Small Cell Lung Cancer. Apr 27, 2017 355
European Commission approves Novartis' drug combination of Tafinlar and Mekinist for lung cancer. Apr 5, 2017 186
European Commission approves Novartis' drug combination of Tafinlar and Mekinist for lung cancer. Apr 5, 2017 182
AstraZeneca passes US FDA approval for TAGRISSO tablets in 80mg for the treatment of non-small cell lung cancer. Apr 3, 2017 249
AstraZeneca passes US FDA approval for TAGRISSO tablets in 80mg for the treatment of non-small cell lung cancer. Apr 3, 2017 245
AstraZeneca gains China approval for lung cancer drug Tagrisso. Mar 28, 2017 206
AstraZeneca gains China approval for lung cancer drug Tagrisso. Mar 28, 2017 202
Roche gets EU approval for lung cancer drug Alecensa. Feb 22, 2017 263
Roche gets EU approval for lung cancer drug Alecensa. Feb 22, 2017 259
AbbVie was granted Orphan Drug Designation by the FDA for veliparib. Jan 1, 2017 138
CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention. Li, Fengzhou; Zhang, Shaofeng; Zhang, Qi; Li, Jinxiu; Zhao, Shilei; Gu, Chundong Report Jan 1, 2017 5588
IASLC 17th WCLC Press Briefing Reveals Advancements in Lung Cancer Treatment Through Immunotherapy and Better Diagnostics. Dec 8, 2016 615
US Food and Drug Administration grants Orphan Drug Designation to AbbVie's veliparib. Nov 8, 2016 169
US Food and Drug Administration grants Orphan Drug Designation to AbbVie's veliparib. Nov 8, 2016 165
AbbVie passes US FDA orphan drug designation for investigational medicine Veliparib for treating NSCLC. Nov 7, 2016 271
AbbVie passes US FDA orphan drug designation for investigational medicine Veliparib for treating NSCLC. Nov 7, 2016 267
Genentech, a member of the Roche Group, received approval from the FDA for TECENTRIQ (atezolizumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following chemotherapy, and have progressed on another targeted therapy if their tumor has EGFR or ALK gene abnormalities. Nov 1, 2016 172
US FDA grants approval to Genentech's Tecentriq. Oct 20, 2016 123
US FDA grants approval to Genentech's Tecentriq. Oct 20, 2016 119
Last-chance lung cancer drug available on NHS. Oct 12, 2016 320
Breakthrough lung cancer drug on NHS; Health. Oct 4, 2016 135
ARIAD Pharmaceuticals completes rolling submission of the New Drug Application for Brigatinib. Sep 1, 2016 200
ARIAD Pharmaceuticals completes rolling submission of the New Drug Application for Brigatinib. Sep 1, 2016 196
Newly identified mutation in NSCLC suggests novel treatment option. Jul 31, 2016 600
AstraZeneca meets primary endpoint in phase III trial assessing lung cancer drug Tagrisso. Jul 19, 2016 143
AstraZeneca meets primary endpoint in phase III trial assessing lung cancer drug Tagrisso. Jul 19, 2016 139
1st new lung cancer drugs for 20 years; Pioneering medicines to boost Scots' survival rates. Jul 12, 2016 284
FDA approves first blood test to detect gene mutation associated with NSCLC. Jul 1, 2016 257
New market study, "NSCLC: Update Bulletin [April 2016] ", has been published. Jun 8, 2016 381
Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer. Zhao, Hua-Ye; Zhou, Hai-Yan; Wang, Yan-Ting; Chen, Wei; Qi, Shu-Ya; Cao, Jun-Ling; Li, Guo-Hui Report Jun 1, 2016 3724
Pfizer receives US FDA approval for Xalkori cancer treatment. Mar 15, 2016 197
Pfizer receives US FDA approval for Xalkori cancer treatment. Mar 15, 2016 193
Pfizer wins US FDA's approval for sNDA for XALKORI for treating patients with ROS1-positive metastatic NSCLC. Mar 14, 2016 328
Pfizer wins US FDA's approval for sNDA for XALKORI for treating patients with ROS1-positive metastatic NSCLC. Mar 14, 2016 324
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. Ni, Jun; Zhang, Li Report Mar 1, 2016 6301
Resolution of vocal fold leukoplakia during erlotinib treatment for lung cancer. Francis, David O.; Misono, Stephanie; Somerville, Jessica; McWhorter, Andrew; Garrett, Gaelyn Feb 1, 2016 1748
Melanoma drug could be used to treat common form of lung cancer. Jan 1, 2016 223
The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Xu, Wei; Jiang, Xinchan; Xu, Zhengyuan; Ye, Tong; Shi, Qionghua Jan 1, 2016 8053
Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review. Xu, Tao; Jin, Zhichao; Yuan, Yuan; Wei, Huamin; Xu, Xinyao; He, Shulin; Chen, Shuntai; Hou, Wei; Guo Jan 1, 2016 10659
Eli Lilly and Company wins US FDA's approval for Portrazza for first-line treatment of metastatic squamous non-small cell lung cancer. Nov 25, 2015 284
Eli Lilly and Company wins US FDA's approval for Portrazza for first-line treatment of metastatic squamous non-small cell lung cancer. Nov 25, 2015 280
US FDA approves Bristol-Myers Squibb's Opdivo injection for lung cancer. Oct 13, 2015 157
US FDA approves Bristol-Myers Squibb's Opdivo injection for lung cancer. Oct 13, 2015 153
Roche announces interim phase II study results for investigational cancer immunotherapy MPDL3280A. May 15, 2015 252
Roche announces interim phase II study results for investigational cancer immunotherapy MPDL3280A. May 15, 2015 248
Bristol Myers Squibb receives US FDA approval for Opdivo to treat lung cancer. Mar 5, 2015 304
Bristol Myers Squibb receives US FDA approval for Opdivo to treat lung cancer. Mar 5, 2015 308
U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer. Feb 2, 2015 808
Novartis, BMS enter clinical immunotherapy alliance. Nov 1, 2014 212
Bristol Myers Squibb receives validation of Marketing Authorisation Application for lung cancer drug. Sep 30, 2014 187
Bristol Myers Squibb receives validation of Marketing Authorisation Application for lung cancer drug. Sep 30, 2014 191
Rare lung cancer susceptible to Pfizer drug. Sep 29, 2014 240
Rare lung cancer susceptible to Pfizer drug. Sep 29, 2014 236
Peregrine Pharmaceuticals' bavituximab obtains FDA Fast Track status for second-line NSCLC treatment. Jan 6, 2014 157
First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. Li, Ying; Wang, Lin Run; Chen, Jian; Lou, Yan; Zhang, Guo Bing Report Jan 1, 2014 4137
OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC. Hao, Yanzhang; Liu, Jianwei; Wang, Ping; Wang, Feng; Yu, Zeshun; Li, Mianli; Chen, Shaoshui; Ning, F Report Jan 1, 2014 3679
Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. Li, Jie-Yao; Duan, Xiu-Fang; Wang, Li-Ping; Xu, Yu-Jie; Huang, Lan; Zhang, Teng- Fei; Liu, Jin-Yan; Report Jan 1, 2014 4514
AFFORDABLE DRUG FOR LUNG CANCER. Dec 15, 2013 183
AFFORDABLE DRUG FOR LUNG CANCER. Dec 15, 2013 293
Pfizer Inc wins US FDA's regular approval for XALKORI for patients with metastatic ALK-positive non-small cell lung cancer. Nov 22, 2013 235
Pfizer Inc wins US FDA's regular approval for XALKORI for patients with metastatic ALK-positive non-small cell lung cancer. Nov 22, 2013 231
Experimental drug could potentially treat lung cancer. Nov 4, 2013 317
CAREMED SELECTED TO DISTRIBUTE TARCEVA. Sep 1, 2013 467
Verifying the role of surgical pathologists in the precision medicine of lung cancer. Cagle, Philip T.; Olsen, Randall J. Editorial Sep 1, 2013 2991
New drug that targets lung cancer genes offers better outcome than chemotherapy. Jun 2, 2013 263
Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Raparia, Kirtee; Villa, Celina; DeCamp, Malcolm M.; Patel, Jyoti D.; Mehta, Minesh P. Report Apr 1, 2013 11577
Diabetes drug could hold promise for treating lung cancer. Jan 30, 2013 583
TechNavio Announces the Publication of Its Research Report - Global Non-Small Cell Lung Cancer Drugs Market 2012-2016. Jan 24, 2013 479
Advancing personalized cancer medicine in lung cancer. MacConaill, Laura E. Oct 1, 2012 5339
Merck collaboration focuses on ovarian cancer treatment. May 21, 2012 375
New gene signature helps in lung cancer''s treatment - reseachers. Apr 20, 2012 618
Gene variant in East Asians could explain resistance to cancer drugs. Mar 19, 2012 712
NICE not to recommend Roche's lung cancer pill. Feb 17, 2012 117
ADVENTRX, FDA agree on ANX-514 study. Oct 27, 2011 186
Randomised, open phase II study of tolerance, safety and efficacy of Viscum album extract in the palliative, additive treatment of advanced non-small cell lung carcinoma (NSCLC). Grah, Christian; Matthes, Burkhard; Happel, Helmut Report Oct 15, 2011 348
Breakthrough melanoma drug ok'd. Sep 26, 2011 371
Duodenal perforation in a patient with non-small cell lung cancer receiving Pemetrexed-Cisplatin combination. Hakeam, H.A.; O'Regan, P.J.; Al-Hshash, G.; Al-Hussieni, H. Case study Sep 1, 2011 1440
Pfizera[euro](tm)s XALKORI receives US FDA approval for lung cancer treatment. Aug 29, 2011 347
Targeted drug therapy found highly effective in lung cancer treatment. Jun 4, 2011 251
Advances in non-small-cell lung cancer treatment: strategies include repeat biopsies and counting circulating cells. Jun 1, 2011 716
Synthetic compound may lead to drugs to fight pancreatic, lung cancer. Mar 10, 2011 298
Crizotinib shows promise against some types of NSCLC. McBride, Deborah Brief article Jan 1, 2011 270
-Danish Topotarget begins phase I/II study with cancer drug. Dec 29, 2010 187
-Danish Topotarget begins phase I/II study with cancer drug. Dec 29, 2010 188
The new drugs available. Nov 24, 2010 155
New drug shows promise against certain lung cancers. Oct 29, 2010 293
Drug slows advanced lung cancer progression in women. McBride, Deborah Brief article Oct 1, 2010 185
Gefitinib may improve progression-free survival from lung cancer. McBride, Deborah Brief article Sep 1, 2010 282
ALK inhibitor has high response in patients with NSCLC. McBride, Deborah Clinical report Aug 1, 2010 331
United Kingdom : Two new cancer treatments approved for use in the NHS. Jul 28, 2010 301
Stockholm-listed Oxigene says patients enrolled for phase II trial with cancer drug. Jun 17, 2010 198
Oxigene presents positive Phase II data for cancer drug. Jun 7, 2010 208
AstraZeneca issues further positive data for Iressa cancer drug. May 3, 2010 293
AstraZeneca issues further positive data for Iressa cancer drug. May 3, 2010 295
FDA grants Fast Track status to Transgene's TG4010 for treatment of non-small cell lung cancer. Dec 2, 2009 219
Stockholm-listed Oxigene releases positive safety data for cancer drug. Nov 18, 2009 221
Cetuximab drug with chemo may cut death risk in lung cancer patients. Sep 22, 2009 310
OSI Pharmaceuticals Inc. Brief article Aug 10, 2009 241
Oncothyreon Inc (Belleview WA) said a long-term follow-up study showed that prolonged treatment with its cancer vaccine Stimuvax was well-tolerated among patients with non-small cell lung cancer, sending its shares up 55%. Brief article Aug 10, 2009 151
mTOR as a validated cancer target. Brief article May 1, 2009 191
Popular cancer drug 'increases blood clot risk'. Dec 3, 2008 458
Popular cancer drug 'increases blood clot risk'. Nov 25, 2008 458
Two drugs don't boost lung cancer survival: Roche. Oct 6, 2008 468
Manage patients with non-small cell lung cancer: as seen in the Clinical Journal of Oncology Nursing. Becze, Elisa Oct 1, 2008 947
Drug lengthened survival in non-small-cell lung ca. Lovinger, Sarah Pressman Clinical report Jul 1, 2007 491
Drug review disappoints; The World Today. Mar 9, 2007 215
Eli Lilly & Co's (Indianapolis IN) Alimta was rejected by a UK government panel for treating a form of lung cancer because it wasn't as cost-effective as Sanofi-Aventis SA's older medicine Taxotere or the best supportive care. Brief article Feb 19, 2007 147
Talactoferrin Alpha receives fast-track designation for the treatment of non-small cell lung cancer. McBride, Deborah Jan 1, 2007 603
Antiangiogenesis drug gets nod for unresectable lung ca. Mechcatie, Elizabeth Nov 15, 2006 579
Bevacizumab approved in lung cancer regimen. Mechcatie, Elizabeth Nov 15, 2006 592
New antiangiogenesis agents fight lung cancer. MacNeil, Jane Salodof Aug 1, 2006 947
Bevacizumab-erlotinib combo boosts lung cancer survival. MacNeil, Jane Salodof Aug 1, 2006 595
Survival not better with chemo for early NSCLC. MacNeil, Jane Salodof Aug 1, 2006 637
Vesicare, Tarceva. Mechcatie, Elizabeth Dec 15, 2004 704
AstraZeneca submits application for new cancer drug to Japanese authorities. Brief Article Jan 28, 2002 105

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |